Oliver Lagore Vanvalin Investment Group Crispr Therapeutics Ag Transaction History
Oliver Lagore Vanvalin Investment Group
- $359 Million
- Q3 2024
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 115 shares of CRSP stock, worth $4,374. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115
Previous 115
-0.0%
Holding current value
$4,374
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$341 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$333 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$145 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$106 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$104 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.97B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....